Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial - Slideshow

Rhythm Pharmaceuticals presented topline results from its Phase 3 EMANATE trial, evaluating setmelanotide for treating rare genetic obesity disorders. The trial assessed efficacy and safety in patients with POMC, PCSK1, or LEPR deficiency. Primary endpoints focused on weight reduction and hunger control after 52 weeks, with secondary measures including metabolic improvements. The company highlighted statistically significant reductions in body weight among participants. Key insights included sustained weight loss in over 80% of patients, with adverse events mostly mild to moderate. The data supports setmelanotide’s potential as a targeted therapy for monogenic obesity. Regulatory submissions are expected in 2026, with plans to expand access via global partnerships. Analysts noted the trial’s success could strengthen Rhythm’s pipeline and market position. The slideshow emphasized long-term benefits, including improved quality of life and reduced obesity-related comorbidities. Investors reacted positively to the trial’s outcomes during the March 2026 presentation.